OBN is the UK’s largest and most innovative not-for-profit R&D Membership organisation for Life Sciences with over 400-member companies, ranging from start-ups through unicorns to Big Pharma, and relevant service sector providers. www.obn.org.uk
Our services include discounted purchasing, professional training, advising, advocacy, networking and partnering via c40 high-quality networking events per year throughout the UK. These are complimented by our four, annual, flag-ship events:
Europe’s leading Biopartnering and Investment conference.
A unique platform for early-stage Life Sciences Companies seeking seed and series-A funding. www.bioseed.eu
A high-quality international partnering conference providing a roadmap for R&D companies looking to achieve sustainable business growth.
OBN AWARDS, Oxford
A leading Life Sciences awards event, celebrating innovation & outstanding achievement across the UK Life Sciences Industry.
Lee PratleyHead of Purchasing and Membership
Oncimmune is working to revolutionise both the detection of cancer and its treatment by harnessing the sophisticated disease detecting capabilities of the immune system to find cancer in its early stages. Our range of diagnostic tests assist clinicians to identify the presence of cancer four years or more before standard clinical diagnosis, whilst our technology platform and sample biobanks are helping healthcare companies to develop new cancer treatments.
Through our recent acquisition of Protagen AG, Oncimmune has expanded its service offering in profiling autoantibodies for the characterisation and prediction of response and adverse events in immuno-oncology and autoimmune diseases.
Mike FisherCommercial Director
Exhibiting at Booth 5
One Nucleus is a membership organisation for international life science and healthcare companies. We are based in Cambridge and London UK, the heart of Europe’s largest life science and healthcare cluster.
Established in 1997, and formerly known as ERBI, One Nucleus is a not-for-profit, membership organisation and located in Cambridge and London – the centre of Europe’s leading life science and healthcare cluster. More than 470 members include pharmaceutical, biotech, medical device and diagnostic companies and associated technical and commercial service providers.
Aline CharpentierHead of Business Development
Oppilotech have developed a high-resolution platform based on systems biology and machine learning to model biological processes in cells. The platform is utilized to identify first-in-class drug targets and to develop novel modes of action drugs modulating the identified targets.The high level of detail allows us to reveal new biology and identify first-in-class non-intuitive drug targets. We initially focused our modelling efforts on E.coli identifying 4 first-in-class antibacterial drug targets and generated active chemical matter against 3 of them. We are now expanding into pathways in human cells allowing us to address a wider range of diseases including cancer (ERK and DNA Damage pathways) and inflammation (cGAS-STING).
Our Business model is to establish:
· Partnerships with Pharma/Biotechs who would like Oppilotech to model pathways they are working on
· Partnerships with Pharma/Biotech who would like access to targets generated from in-house modelling of pathways
· Partnership with Pharma/Biotechs who would like access to early stage drug development programmes developed by Oppilotech on targets identified in-house
· Partnerships on our antibacterial programmes
Oxford Biomedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, Axovant Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 430 people.
Andrew LewinVP, Business Development Manufacturing
Aurelie CharpentierManager, Business Development
Jeremy HarropVP, Business Development Product Licensing
OxStem is a drug discovery company, spun-out from the University of Oxford in 2016, with the unique vision of developing small molecule therapeutics that augment repair mechanisms that already exist within the body. OxStem is developing drug candidates that can awaken endogenous cells to repair tissues affected by disease or injury to treat diseases such as Dementia, Heart Failure, Macular Degeneration (the leading cause of blindness in the developed world) and Oncology.